Blood-Vessel-on-a-Chip Technology Accelerates Virus Research

A Dutch research team has developed a blood-vessel-on-a-chip device that accelerates virology research by mimicking human microvasculature in the lab, according to a report published June 26, 2026, by Trouw. The technology, created by scientists at the University Medical Center Utrecht (UMCU), allows researchers to study how viruses like SARS-CoV-2 and influenza interact with human blood vessels in real time, potentially cutting months off drug development timelines.

The device replicates the endothelial cell lining of capillaries and venules, which viruses often target during infection. Early tests with SARS-CoV-2 showed the chip could identify viral entry points within 48 hours—a process that previously required weeks of animal studies or complex cell cultures. "This is a game-changer for antiviral research," said Dr. Jeroen van den Berg, a virologist at UMCU and lead investigator, in an interview with Trouw. "We can now test hundreds of compounds in parallel, something impossible with traditional models."

UMCU researchers collaborated with Philips Research to integrate the chip with automated fluidics and imaging systems, enabling continuous monitoring of viral replication and immune responses. The technology has already been used to screen potential treatments for a newly identified respiratory virus, though details remain under review for peer publication. A preprint study on the chip’s design, posted June 20 on bioRxiv, described its ability to replicate vascular inflammation patterns seen in COVID-19 patients, suggesting applications beyond virology, including cardiovascular drug testing.

The chip’s development follows a push by European health authorities to reduce reliance on animal testing in infectious disease research. In 2025, the European Medicines Agency (EMA) issued guidelines encouraging the adoption of "organ-on-a-chip" models for preliminary toxicity screening, citing ethical concerns and cost savings. UMCU’s device aligns with these efforts, though regulatory approval for clinical use remains years away. "This isn’t a replacement for human trials," noted Dr. Anja Wolbers, a bioengineer at the University of Twente, who was not involved in the study. "But it’s a critical step in narrowing down candidates before expensive Phase I testing."

Comparisons with existing models highlight the chip’s advantages. Traditional 2D cell cultures lack vascular structure, while animal models introduce variability and ethical hurdles. A 2024 study in Nature Methods found that mouse models of SARS-CoV-2 infection produced inconsistent results when compared to human tissue responses—a gap the new chip may bridge. UMCU estimates the device could reduce early-stage antiviral screening time by up to 70%, though scalability remains a challenge. The team is seeking partnerships with pharmaceutical companies to adapt the technology for industry use.

What remains uncertain is whether the chip’s findings will translate directly to human responses. Viruses like influenza and SARS-CoV-2 exploit host-specific receptors, and while the chip mimics endothelial cells, other tissue interactions may still require animal or clinical validation. "We’re not claiming this is a silver bullet," van den Berg told Trouw. "But for the first time, we can study vascular infections in a way that’s closer to reality than ever before."

The next phase involves expanding the chip’s capabilities to include lymphatic vessels and immune cell interactions, which could improve research into autoimmune diseases and cancer metastasis. UMCU has filed a provisional patent and is in discussions with the Dutch Ministry of Health to explore public funding for further development. Meanwhile, academic labs in Germany and the U.S. are reportedly developing similar vascular-mimicking devices, though none have achieved the same level of integration with virology research.

For readers tracking advancements in lab-grown human tissues, this development underscores a broader trend: the shift toward "humanized" research models that prioritize biological relevance over traditional animal testing. The chip’s success could accelerate not only antiviral drug discovery but also personalized medicine approaches, where vascular responses to treatments are critical. However, as with all emerging technologies, the key question is whether the gains in speed and precision will outweigh the costs of implementation in global health research pipelines.